Learn more →
Back to Expert Scholars
hematopoietic-transplant / hematopoietic-transplantReduced-Intensity Conditioning

Corey Cutler

科里·卡特勒

MD, MPH, FRCPC

🏢Dana-Farber Cancer Institute / Brigham and Women's Hospital(丹娜-法伯癌症研究所/布莱根妇女医院)🌐USA

Medical Director, Stem Cell Transplantation Program; Associate Professor, Harvard Medical School干细胞移植项目医疗主任,哈佛医学院副教授

58
h-index
3
Key Papers
3
Awards
3
Key Contributions

👥Biography 个人简介

Corey Cutler is an internationally recognized leader in allogeneic hematopoietic cell transplantation, with particular expertise in reduced-intensity conditioning regimens that have expanded transplant access to older and medically unfit patients. His clinical and health outcomes research has shaped contemporary transplant decision-making globally.

Share:

🧪Research Fields 研究领域

Reduced-Intensity Conditioning减低强度预处理
Older Patient Transplant老年患者移植
HSCT造血干细胞移植
GvHD ProphylaxisGvHD预防

🎓Key Contributions 主要贡献

Reduced-Intensity Conditioning Regimens

Conducted landmark randomized trials comparing myeloablative and reduced-intensity conditioning, defining optimal approaches for different patient populations and disease types.

Transplant Outcomes in Older Adults

Led seminal research establishing the feasibility and efficacy of allogeneic HSCT in patients over 60, challenging age-based exclusion criteria and expanding transplant eligibility.

GvHD Prophylaxis Optimization

Contributed to trials of novel GvHD prophylaxis strategies including post-transplant cyclophosphamide and sirolimus-based regimens across matched and alternative donor settings.

Representative Works 代表性著作

[1]

Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

Journal of Clinical Oncology (2013)

BMT CTN 0901 trial comparing conditioning intensity in AML/MDS, providing practice-defining evidence for transplant decision-making.

[2]

Sirolimus and tacrolimus without calcineurin inhibitor exposure criteria does not impair renal function after allogeneic HCT

Blood (2014)

Established safety profile of sirolimus-based GvHD prophylaxis with implications for organ function preservation.

[3]

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Blood (2014)

Randomized comparison establishing sirolimus-based prophylaxis as superior for acute GvHD prevention.

🏆Awards & Recognition 奖项与荣誉

🏆American Society for Transplantation and Cellular Therapy New Investigator Award
🏆Harvard Medical School Teaching Award
🏆Best Doctors in America

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 科里·卡特勒 的研究动态

Follow Corey Cutler's research updates

留下邮箱,当我们发布与 Corey Cutler(Dana-Farber Cancer Institute / Brigham and Women's Hospital)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment